Colposcopy in India and UAE | Complete Patient Guide

• Women with an abnormal Pap smear result: atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells — cannot exclude HSIL (ASC-H), low-grade squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL)

• Women with a positive hrHPV test (especially HPV 16 or 18) regardless of cytology result, as per risk-based management guidelines (ASCCP 2019)

• Women with unexplained post-coital bleeding, intermenstrual bleeding, or persistent vaginal discharge not explained by infection

• Women with a clinically suspicious-looking cervix on speculum examination (irregular surface, friable tissue, contact bleeding)

• Follow-up surveillance after prior treatment for CIN, VAIN, or cervical cancer

• Women with a history of DES (diethylstilbestrol) in utero exposure

• Evaluation of VIN (vulvar intraepithelial neoplasia) or VAIN (vaginal intraepithelial neoplasia) in conjunction with extended colposcopy

Required Pre-Procedure Diagnostics:

• Recent Pap smear / LBC cytology report and HPV genotyping result (within 12 months)

• Transvaginal ultrasound (TVS) if uterine or adnexal pathology is suspected

• STI screen (Chlamydia, Gonorrhoea, Trichomonas) — active pelvic infection is a relative contraindication

• Beta-hCG (urine or serum pregnancy test) — colposcopy can be performed in pregnancy, but ECC is contraindicated

• Complete blood count (CBC) and coagulation profile (PT/INR, aPTT) if biopsy or excision is anticipated

• Renal and liver function tests if patient is on anticoagulant therapy

Contraindications:

• Active, uncontrolled pelvic inflammatory disease (PID) — defer until treated

• Endocervical curettage (ECC): absolutely contraindicated in pregnancy

• Anticoagulation therapy (relative): requires bridging plan in coordination with haematology

• Severe vaginal atrophy making speculum insertion traumatic — pre-treat with topical oestrogen for 4–6 weeks

Colposcopy encompasses both a diagnostic procedure and, where clinically indicated, same-session therapeutic intervention. The following techniques represent the current spectrum of colposcopic practice at advanced gynaecological centres:

1. STANDARD DIAGNOSTIC COLPOSCOPY

Performed under direct colposcopic visualisation using a Leisegang, Zeiss, or equivalent binocular colposcope. Sequential application of 3–5% acetic acid followed by Lugol's iodine allows grading of the transformation zone type (TZ1: fully ectocervical and visible; TZ2: partially endocervical; TZ3: fully endocervical) per IFCFC 2011 criteria. Colposcopically directed punch biopsies (1–4 samples) are taken from the highest-grade areas. ECC is added when TZ3 is present or when cytology-colposcopy discordance exists (cytology HSIL but colposcopy low-grade).

2. DIGITAL VIDEO COLPOSCOPY WITH AI-ASSISTED IMAGE ANALYSIS

High-definition (HD) digital colposcopes (e.g., Lutech, Olympus OCS-500) capture real-time video and still images for archiving, second-opinion review, and AI-assisted acetowhite lesion detection. Several JCI-accredited centres in India and the UAE now use machine-learning algorithms (e.g., CAIIBM, EVA colposcopy software) trained on thousands of colposcopic images to flag Grade 2 lesions with sensitivity comparable to expert colposcopists, reducing inter-observer variability.

3. NARROW BAND IMAGING (NBI) COLPOSCOPY

NBI uses filtered light (415 nm blue, 540 nm green) to enhance visualisation of superficial capillary architecture — punctation, mosaicism, and atypical vessels — without acetic acid application. This technique is particularly valuable in postmenopausal or immunocompromised patients where acetowhitening is less pronounced and in identifying the neovascular patterns of early invasive disease (IFCPC 2011: irregular vessels, necrosis, wide intercapillary distance).

4. LARGE LOOP EXCISION OF THE TRANSFORMATION ZONE (LLETZ / LEEP)

The most commonly performed excisional treatment for CIN 2–3. A thin wire loop electrode (15–25 mm width, 8–12 mm depth) energised at 30–50 W blend current (electrosurgical unit: Valleylab FT10, ERBE VIO) excises the entire transformation zone en bloc under local anaesthetic (cervical block: 2–4 mL 1% lignocaine with 1:100,000 adrenaline at 3, 5, 7, and 9 o'clock). The LLETZ specimen provides a histological margin assessment — endocervical and ectocervical margins — guiding the adequacy of excision. Same-session see-and-treat LLETZ (colposcopy + LLETZ in one visit) is offered to patients with high clinical probability of CIN 2–3 (HSIL cytology + Grade 2 colposcopy).

5. COLD-KNIFE CONISATION (CKC)

Reserved for adenocarcinoma in situ (AIS), recurrent CIN after LLETZ, or a TZ3 that is inadequately accessible to loop excision. A scalpel cone is taken under general or spinal anaesthesia, providing a larger specimen with thermal-artefact-free margins — critical for precise histological interpretation of glandular lesions.

6. ABLATIVE THERAPIES (selected cases of CIN 1–2 with fully visible TZ1–2)

• Cryotherapy: Nitrous oxide or CO₂ at −89°C applied in a 3-minute freeze / 5-minute thaw / 3-minute freeze protocol. Suitable for CIN 1 in resource-limited or screen-and-treat settings (WHO guidelines).

• Laser Ablation (CO₂ laser, 10,600 nm): Precise depth control (5–7 mm) under colposcopic guidance; preferred for multifocal or large-area CIN in well-equipped centres in India and UAE.

• Thermal Ablation / Thermocoagulation: Contact thermocoagulation at 100–120°C; increasingly used in low-resource WHO screen-and-treat programmes.

7. HPV VACCINATION AS ADJUNCT (post-treatment)

For patients under 45 years with no prior vaccination, quadrivalent (Gardasil-4) or nonavalent (Gardasil-9) HPV vaccination is recommended post-LLETZ to reduce the risk of recurrent CIN from residual or re-acquired HPV infection, supported by randomised controlled evidence (Joura et al., NEJM 2012).

PRE-PROCEDURE (Days –7 to –1):

• GAF Healthcare patient coordinator reviews all prior cytology, HPV test results, and imaging reports and shares them with the assigned colposcopist for pre-procedure planning.

• Pelvic infection screen and pregnancy test are completed within 7 days of procedure.

• Patient is advised to schedule the procedure for mid-cycle (days 10–20) to avoid menstrual blood obscuring visualisation — though colposcopy can be performed at any time.

• Avoid intercourse, vaginal douching, and intravaginal medications for 24 hours prior.

• If anticoagulants (warfarin, DOACs) are in use, haematology consultation is arranged 5–7 days in advance for bridging protocol.

• No fasting required (procedure is outpatient under local anaesthetic or without anaesthesia).

DAY OF PROCEDURE:

• Patient arrives at the colposcopy clinic or outpatient gynaecology unit 30–60 minutes before the appointment.

• Consent is obtained covering the procedure, biopsy, possible LLETZ, and risks (bleeding, infection, mild cramping).

• Patient is placed in dorsal lithotomy position; a bivalve speculum is inserted.

• Cervix is cleaned with normal saline; acetic acid 3–5% is applied — patients may feel mild stinging.

• Colposcopic examination takes 10–20 minutes for diagnostic colposcopy alone.

• Directed biopsies are taken (1–4 samples) using Kevorkian or Eppendorfer forceps — patient experiences a brief, sharp pinch with each biopsy.

• ECC, if indicated, takes 1–2 additional minutes; produces uterine cramping similar to dysmenorrhoea.

• If same-session LLETZ is performed, a cervical block is administered (onset 2–3 minutes), loop excision takes 2–5 minutes, and haemostasis is achieved with ball-electrode coagulation or Monsel's ferric subsulfate solution.

• Total procedure time: 20–45 minutes.

• Patient rests in recovery for 30–60 minutes, then is discharged home.

IMMEDIATE POST-PROCEDURE (Hours 1–24):

• Mild pelvic cramping for 2–6 hours — managed with ibuprofen 400 mg or paracetamol 1 g orally.

• Light vaginal spotting or dark brown discharge (from Monsel's solution) is expected and normal for 1–3 days after biopsy; up to 2–3 weeks after LLETZ.

• Patient is advised to avoid sexual intercourse, tampons, and swimming for 4 weeks post-LLETZ (2 weeks post-biopsy only).

• Avoid strenuous exercise for 1 week post-biopsy; 2–3 weeks post-LLETZ.

SHORT-TERM RECOVERY (Days 2–14):

• Histopathology results are typically available within 5–10 business days (expedited 3–5 days at premium centres).

• GAF Healthcare coordinates secure digital transfer of histology reports to the patient's home-country gynaecologist.

• Warning signs requiring immediate medical attention: heavy bleeding (soaking more than one pad per hour), fever >38°C, foul-smelling discharge, or severe abdominal pain — patients are provided 24/7 GAF Healthcare emergency contact.

FIT-TO-FLY MILESTONES:

• Diagnostic colposcopy with biopsy only: fit to fly within 3–5 days if no significant bleeding and histology can be transferred digitally.

• Colposcopy + LLETZ/LEEP: fit for short-haul flight (under 4 hours) in 5–7 days; long-haul international flight in 7–10 days, once bleeding has settled, infection risk window has passed, and histology is available.

• Patient is provided a fit-to-fly letter by the treating gynaecologist.

LONG-TERM FOLLOW-UP (Months 1–24):

• Post-biopsy (CIN 1): surveillance HPV/cytology co-test at 12 months, then 24 months.

• Post-LLETZ (CIN 2–3): test of cure HPV test at 6 months; if hrHPV negative and cytology normal, return to routine 3-year screening.

• Post-LLETZ (AIS): annual surveillance for 5 years given higher recurrence risk.

• All follow-up is coordinated with the patient's local gynaecologist via GAF Healthcare's international care continuity programme.